This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.
This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨
This week, we will continue with February’s aldosterone leitmotif: do mineralocorticoid receptor antagonists (MRAs) truly blind the diagnostic in unilateral hypraldosteronism? Is this the article the mythbuster? Draw your own conclusions
This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?
Check out the home page - great job by Peter Gallacher putting it together. See you all on April 26th or 27th. We hope to have an author online at the chat too. More soon!
This was another great #NephJC. Notable for many firsts:
The transcripts and storifys are also already done - and up on the page, due to uber-fast curation from Hector.
Lastly, we have the pleasure of announcing the winners of the coveted #NEJMCup. There were many great tweets, so it took some time to sift through all the nominees. Here are the winning tweets:
T1: If faced the option of wait listing or incompatible living donor, I would be willing to take the risk #NephJC
— Kevin J. Fowler (@gratefull080504) April 13, 2016
@NephJC @calvapo #nephjc UK data also shows advantage but less impressive. Patient choice and expectation so important
— Sian Griffin (@toomuchaltitude) April 13, 2016
Congratulations, Kevin and Sian! Your #NEJMCups should be on the way soon, courtesy of the New England Journal of Medicine.
